Health Evidence Network synthesis report 53
This paper looks at the status of tuberculosis (TB) advocacy
communication and social mobilization (ACSM) activities in selected
national TB control programmes in the WHO African Region. The
findings are from an assessment of TB ACSM activities in Ghana, Kenya,
Lesotho, Malawi and South Africa.
...
Disease control, issue 15
The African health monitor
Accessed November 2017
more
Journal of the International Association of Providers of AIDS Care 2017, Vol. 16(3) 226–232
Key populations brief
Accessed 2017
СЕЛЬСКОЕ НАСЕЛЕНИЕ
ОСНОВНЫЕ ЗАТРОНУТЫЕ ГРУППЫ НАСЕЛЕНИЯ. КРАТКОЕ РУКОВОДСТВО.
Scientific advice
Prevention and control of communicable diseases in prison settings.
Public Health Situation Analysis and Interventions 10 October 2017
TB policies in 29 Countries
A survey of prevention, testing and treatment policies and practices
Conclusion: To ensure that people with disabilities can successfully access the necessary health services, the barriers on the demand side (the individuals requiring healthcare) as well as the barriers that are part of the healthcare system, should be attended to.
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 23, No. 11, November 2017
UNAIDS 2017 / Reference
Generating evidence for policy and action on HIV and social protection
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
Information note
Accessed November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
РУКОВОДСТВО ДЛЯ АКТИВИСТОВ ПО ИНСТРУМЕНТАМ ДЛЯ ДИАГНОСТИКИ ТУБЕРКУЛЕЗА ЯНВАРЬ.
The International Journal of Tuberculosis and Lung Disease 21(5) DOI: 10.5588/ijtld.16.0518
National Tuberculosis and Leprosy Control Program
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more